BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12107232)

  • 1. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?
    Robbins RJ; Chon JT; Fleisher M; Larson SM; Tuttle RM
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3242-7. PubMed ID: 12107232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
    Mazzaferri EL; Robbins RJ; Spencer CA; Braverman LE; Pacini F; Wartofsky L; Haugen BR; Sherman SI; Cooper DS; Braunstein GD; Lee S; Davies TF; Arafah BM; Ladenson PW; Pinchera A
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1433-41. PubMed ID: 12679418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later.
    Kloos RT; Mazzaferri EL
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5047-57. PubMed ID: 15972576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
    Robbins RJ; Tuttle RM; Sharaf RN; Larson SM; Robbins HK; Ghossein RA; Smith A; Drucker WD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma.
    Robbins RJ; Srivastava S; Shaha A; Ghossein R; Larson SM; Fleisher M; Tuttle RM
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6010-6. PubMed ID: 15579752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal.
    Cherk MH; Francis P; Topliss DJ; Bailey M; Kalff V
    Clin Endocrinol (Oxf); 2012 May; 76(5):734-40. PubMed ID: 22050475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
    Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
    J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
    Spencer CA; LoPresti JS; Fatemi S; Nicoloff JT
    Thyroid; 1999 May; 9(5):435-41. PubMed ID: 10365673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
    Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.
    David A; Blotta A; Bondanelli M; Rossi R; Roti E; Braverman LE; Busutti L; degli Uberti EC
    J Nucl Med; 2001 Oct; 42(10):1470-5. PubMed ID: 11585859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulated thyroglobulin at recombinant human TSH-aided ablation predicts disease-free status one year later.
    Melo M; Costa G; Ribeiro C; Carrilho F; Martins MJ; da Rocha AG; Sobrinho-Simões M; Carvalheiro M; Soares P
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4364-72. PubMed ID: 24037891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer.
    Alzahrani AS; AlShaikh O; Tuli M; Al-Sugair A; Alamawi R; Al-Rasheed MM
    Clin Nucl Med; 2012 Mar; 37(3):229-34. PubMed ID: 22310247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.
    Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR
    Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin.
    Wartofsky L;
    Thyroid; 2002 Jul; 12(7):583-90. PubMed ID: 12193302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the recombinant human TSH stimulated thyroglobulin level and diagnostic whole body scan in children with differentiated thyroid carcinoma.
    Hoe FM; Charron M; Moshang T
    J Pediatr Endocrinol Metab; 2006 Jan; 19(1):25-30. PubMed ID: 16509525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement.
    Pacini F; Lippi F
    J Endocrinol Invest; 1999; 22(11 Suppl):25-9. PubMed ID: 10727002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.